15

1. A compound of the formula:

A₀-A₁-A₂-A₃-A₄-A₅-A₆/A₇-A₈-A₉-A₁₀

or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein: $A_0 \text{ is hydrogen or an acyl group selected from:}$

- (1) R-(CH₂)_n-C(O)-; wherein n is an integer from 0 to 8 and R is selected from hydroxyl; methyl; N-acetylamino; methoxyl; carboxyl; cyclohexyl optionally containing a one or two double bonds and optionally substituted with one to three hydroxyl groups; and a 5- or 6-membered ring aromatic or nonaromatic ring optionally containing one or two heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the ring is optionally substituted with a moiety selected from alkyl, alkoxy, and halogen; and
- (2) /R¹-CH₂CH₂-(OCH₂CH₂O)_p-CH₂-C(O)-; wherein R¹ is selected from hydrogen, alkyl, and N-acetylamino, and p is an integer from 1 to 8;

A₁ is an amino acyl residue selected from:


- (1) alanyl,
- (2) asparaginyl,
- (3) citrullyl,
- (4) glutaminyl,
- (5) glutamyl,
- (6) N-ethylglycyl,
- (7) methionyl,
- (8) N-methylalanyl,
- (9) prolyl,
- (10) pyro-glutamyl,
- (11) sarcosyl,

25

20

		/,
	(15)	t-butylglycyl,
	(16)	threonyl,
	(17)	valyl,
65	(18)	penicillaminyl, and
	(19)	cystyl;
	A ₄ is an amin	o acyl residue of L or D configuration selected from:
	(1)	allo-isoleucyl,
	(2)	glycyl,
70	(3)	isoleucyl,
	(4)	prolyl,
	(5)	dehydroleucyl,
	(6)	D-alanyl,
	(7)	D-3-(naphth-1-y))alanyl,
75	(8)	D-3-(naphth-2-yl)alanyl,
	(9)	D-(3-pyridyl)/alanyl,
	(10)	D-2-aminobyltyryl,
	(11)	D-allo-isoleucyl,
	(12)	D-allo-threonyl,
80	(13)	D-allylglycyl,
	(14)	D-asparaginyl,
	(15)	D-aspartyl,
	(16)	D-benzothienyl,
	(17)	D-3-(4,4'-biphenyl)alanyl,
85	(18)	D-chlorophenylalanyl,
	(19)	D-3/(3-trifluoromethylphenyl)alanyl,
	(20)	D-\$-(3-cyanophenyl)alanyl,
	(21)	D/3-(3,4-difluorophenyl)alanyl,
	(22)	D-citrullyl,
90	(23)	D-cyclohexylalanyl,
	(24)	D-cyclohexylglycyl,
	(25)	D-cystyl,
	(26)	D-cystyl(S-t-butyl),
	/	
	1	

		(27)	D-glutaminyl,
	95	(28)	D-glutamyl,
		(29)	D-histidyl,
		(30)	D-homoisoleucyl,
		(31)	D-homophenylalanyl,
		(32)	D-homoseryl,
	100	(33)	D-isoleucyl,
		(34)	D-leucyl,
		(35)	D-lysyl(N-epsilon-nicotinyl),
		(36)	D-lysyl,
		(37)	D-methionyl,
	105	(38)	D-neopentylglycyl,
. H.		(39)	D-norleucyl,
		(40)	D-norvalyl,
=======================================		(41)	D-ornithyl/
Ü		(42)	D-penicillaminyl,
	110	(43)	D-penic llaminyl (acetamidomethyl),
÷		(44)	D-penicillaminyl(S-benzyl),
i di		(45)	D-phenylalanyl,
		(46)	D-3/(4-aminophenyl)alanyl,
u 11u		(47)	D-3-(4-methylphenyl)alanyl,
i ii	115	(48)	D/3-(4-nitrophenyl)alanyl,
		(49)	\$\psi_{-3-(3,4-dimethoxyphenyl)alanyl,}\$
		(50)	D-3-(3,4,5-trifluorophenyl)alanyl,
		(51)	D-prolyl,
		(52)	D-seryl,
	120	(53/)	D-seryl(O-benzyl),
		(5/4)	D-t-butylglycyl,
		(55)	D-thienylalanyl,
		(56)	D-threonyl,
		(57)	D-threonyl(O-benzyl),
	125	(58)	D-tryptyl,



170

175

180

185





(28) cystyl;

A₆ is an amino acyl residue of L or D configuration selected from:

160 (1) alanyl,

- (2) 3-(naphth-1-yl)alanyl,
- (3) 3-(naphth-2-yl)alanyl,
- (4) (3-pyridyl)alanyl,
- (5) 2-aminobutyryl,
- (6) allylglycyl,
- (7) arginyl,
- (8) asparaginyl,
- (9) aspartyl,
- (10) citrullyl,
- (11) cyclohexylalanyl,
- (12) glutaminyl,
- (13) glutanyl,
- (14) glycyl,
- (15) histidyl,
- (16) homoalanyl,
- (17) /homoleucyl,
- (18) / homoseryl,
- (19) isoleucyl,
- $(2\emptyset)$ leucyl,
- (21) lysyl(N-epsilon-acetyl),
- (22) lysyl(N-epsilon-isopropyl),
- (23) methionyl(sulfone),
- (24) methionyl(sulfoxide),
- (25) methionyl,
- (26) norleucyl,
- (27) norvalyl,
- (28) octylglycyl,
- (29) phenylalanyl,
- (30) 3-(4-carboxyamidephenyl)alanyl,





			\nearrow
		(21)	3-(4-amino-N-isopropylphenyl)alanyl;
	255	A ₉ is an amino	acyl residue of L or D configuration selected from:
		(1)	2-amino-butyryl,
		(2)	2-amino-isobutyryl,
		(3)	homoprolyl,
		(4)	hydroxyprolyl,
	260	(5)	isoleucyl,
		(6)	leucyl,
		(7)	phenylalanyl,
		(8)	prolyl,
		(9)	seryl,
	265	(10)	t-butylglycyl,
		(11)	1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
		(12)	threonyl,
== == ==		(13)	valyl,
THE STATE OF		(14)	D-alany), and
	270	(15)	D-prolyl; and
22		A ₁₀ is a hydro	xyl group or an amino acid amide is selected from:
And		(1)	azaglycylamide,
fu fii		(2)	D-a/anylamide,
		(3)	D-alanylethylamide,
2	275	(4)	glycylamide,
		(5)	glycylethylamide,
		(6)	/sarcosylamide,
		(7)	/ serylamide,
		(8)	D-serylamide,
	280	(9)	a group represented by the formula
			-NH-(CH ₂) _s -CHR ³ , and
			-NH-(CH ₂) _s -CHR ^s , and
		(10)	a group represented by the formula -NH-R ⁴ ;
		/	
		/	
		/	

10

15

wherein:

s is an integer selected from 0 to 8,

285

290

R² is selected from hydrogen, alkyl, and a 5- to 6-membered cycloalkyl ring;

R³ is selected from hydrogen, hydroxy, alkyl, phenyl, alkoxy, and a 5- to 6-membered ring optionally containing from one to two heteroatoms selected from oxygen, nitrogen, and sulfur, provided that s is not zero when R³ is hydroxy or alkoxy; and

D⁴:

R⁴ is selected from hydrogen, hydroxy, and a 5- to 6-membered cycloalkyl ring.

- 2. A compound according to Claim 1, wherein A_1 is sarcosyl, A_2 is glycyl, A_3 is valyl, A_7 is isoleucyl, A_8 is arginyl, A_9 is prolyl, and A_0 , A_4 , A_5 , A_6 , and A_{10} are as defined in Claim 1.
- 3. A compound according to Claim 2, wherein A₄ is an amino acyl residue having a D configuration selected from:
 - (1) D-alanyl,
 - (2) D-3-(naphth-1-yl)alanyl,
 - (3) D-3-(naphth-2-yl)alanyl,
 - (4) D-(3-pyridyl)-alanyl,
 - (5) D-2-aminobutyryl,
 - (6) D-allo-isoleucyl,
 - (7) D-allo-threonyl,
 - (8) D-allylglycyl,
 - (9) D-asparaginyl,
 - (10) D-aspartyl,
 - (11) D-chlorophenylalanyl,
 - (12) D-3-(3-trifluoromethylphenyl)alanyl,
 - (13) D-3-(3-cyanophenyl)alanyl,
 - (14) D-3-(3,4-difluorophenyl)alanyl,
 - (15) D-cyclohexylalanyl,

(47)

D-tyrosyl(*O*-ethyl),

10

5

5

4.	A con	npound according to Claim 3, wherein A4 is an amino acyl residu
having a D configuration selected from:		
	(1)	D-allo-isoleucyl,
	(2)	D-allylglycyl,
	(3)	D-3-(3-cyanophenyl)alanyl,
	(4)	D-cystyl,
	(5)	D-isoleucyl,
	(6)	D-leucyl,
	(7)	D-penicillaminyl,
	(8)	D-phenylalanyl,
	(9)	D-3-(3,4,5-trifluorophenyl)alanyl, and
	(10)	D-3-(4-aminophenyl)alanyl.
5.	A con	npound according to Claim 2, wherein A ₅ is selected from:
	(1)	glycyl,
	(2)	octylglycyl,
	(3)	penicillaminyl,
	(4)	seryl,
•	(5)	threonyl, and
	(6)	tyrosyl.
6.	A con	npound according to Claim 2, wherein A ₆ is selected from:
	(1)	glutaminyl,
	(2)	leucyl,
	(3)	norvalyl, and


D-tyrosyl, and

(48)

(49) D-valyl.

seryl.

(4)



	(11)	2-(methoxy)ethylamide,
	(12)	2-(hydroxy)ethylamide,
15	(13)	2-(2-pyridine)ethylamide,
	(14)	(2-pyridine)methylamide,
	(15)	2-(3-pyridine)ethylamide,
	(16)	2-(2-(1-methyl)pyrrolidine)ethylamide,
	(17)	2-(N-morpholine)ethylamide, and
20	(18)	cyclopropylmethylamide.
	9. A con	apound according to Claim 1, wherein A ₄ is an amino acyl residue
	having a D configura	tion selected from:
	(1)	D-allo-isoleucyl,
5	(2)	D-allylglycyl,
	(3)	D-3-(3-cyanophenyl)alanyl,
	(4)	D-cystyl,
	(5)	D-isoleucyl,
	(6)	D-leucyl,
10	(7)	D-penicillaminyl,
	(8)	D-phenylalanyl,
	(9)	D-3-(3,4,5-trifluorophenyl)alanyl, and
	(10)	D-3-(4-aminophenyl)alanyl;
	A ₅ is an amin	o acyl residue selected from:
15	(1)	octylglycyl,
	(2)	glycyl,
	(3)	penicillaminyl,
	(4)	seryl,
	(5)	threonyl, and
20	(6)	tyrosyl; and
	A ₆ is an amin	o acyl residue selected from:
	(1)	glutaminyl,
	(2)	leucyl,
	(3)	norvalyl, and

(4) seryl.

10. A compound according to Claim 9, wherein A_0 is selected from:

- (1) acetyl,
- (2) butyryl,
- (3) caproyl,
- (4) (4-Nacetylamino)butyryl,
- (5) N-acetyl-beta-alanyl,
- (6) (6-N-acetylamino)caproyl,
- (7) chloronicotinyl,
- (8) cyclohexylacetyl,
- (9) furoyl,
- (10) gamma-amindbutyryl,
- (11) 2-methoxyacetyl,
- (12) methylnicotinyl,
- (13) nicotinyl,
- (14) (8-N-acetylamino)-₹,6-dioxo-octanoyl,
- (15) phenylacetyl,
- (16) propionyl,
- (17) shikimyl,
- (18) succinyl, and
- (19) tetrahydrofuroyl.

11. A compound according to Claim 9, wherein A_{10} is selected from:

- (1) D-alanylamide,
- (2) azaglycylamide,
- (3) serylamide
- (4) ethylamide,
- (5) hydroxylamide,
- 30 (6) isopropylamide,
 - (7) propylamide,

10

25

		(8) 2-(Cyclonexyl)ethylamue,
		(9) 2-(1-pyrrolidine)ethylamide,
		(10) 1-(cyclohexyl)ethylamide,
		(11) 2-(methoxy)ethylamide,
5		(12) 2-(hydroxy)ethylamide,
		(13) 2-(2-pyridine)ethylamide,
		(14) (2-pyridine)methylamide,
		(15) 2-(3-pyridine)ethylamide,
		(16) 2-(2-(1-methyl)pyrrolidine)ethylamide,
10		(17) 2-(N-morpholine)ethylamide, and
		(18) cyclopropylmethylamide.
(
K/\	12.	A compound, or a pharmaceutically acceptable salt, ester, solvate or
p_1	rodrug there	eof, selected from:
15	(1)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	(2)	pyroGlu-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	(3)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH3,
	(4)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nya-Ile-Arg-ProNHCH2(CH3)2,
	(5)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH2-(1-pyrrolidine),
20	(6)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHethylpiperidine,
	(7)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHmethylcyclopropyl,
	(8)	N-Ac-Sar-Gly-Val-D-IJe-Thr-Nva-Ile-Arg-ProNH(ethyl-1-(R)-cyclohexyl),
	(9)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNH ₂ ,
	(10)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₂ OCH ₃ ,
25	(11)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH2cyclohexyl,
	(12)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
	(13)	N-Ac-Sar-Gly/Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	(14)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	(15)	N-Ac-Sar-Gly-Val-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
30	(16)	N-Ac-Sar/Gly-Val-Gly-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	(17)	N-Ac-Sar-Gly-Val-D-Val-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	(18)	N-Ac-Sar-Gly-Val-D-Ala-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	(19)	N-Ac/Sar-Gly-Val-D-Met-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		- 209 -
		V

The second second with the second sec

(8) 2-(cyclohexyl)ethylamide,

		(20)	N-Ac-Sar-Gly-Val-D-Nle-Thr-Nva-Ile-Arg-ProNHCL/2CH3,
		(21)	N-Ac-Sar-Gly-Val-D-Phe-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(22)	N-Ac-Sar-Gly-Val-D-Tyr-Thr-Nva-Ile-Arg-ProNACH ₂ CH ₃ ,
		(23)	N-Ac-Sar-Gly-Val-D-4,4 Biphenylala-Thr-Nva/Ile-Arg-ProNHCH ₂ CH ₃ ,
	5	(24)	N-Ac-Sar-Gly-Val-D-Cha-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(25)	N-Ac-Sar-Gly-Val-D-Chg-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(26)	N-Ac-Sar-Gly-Val-D-4-ClPhe-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(27)	N-Ac-Sar-Gly-Val-D-Hphe-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(28)	N-Ac-Sar-Gly-Val-Dehydroleu-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	10	(29)	N-Ac-Sar-Gly-Val-D-3-CF ₃ Phe-Thy-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(30)	N-Ac-Sar-Gly-Val-D-pentaFPhe-Thr-Nva-Ile-Arg-ProNHCH2CH2
		(31)	N-Ac-Sar-Gly-Val-D-3,4-diClPhe-Thr-Nva-Ile-Arg-ProNHCH2CH2
Ē		(32)	N-Ac-Sar-Gly-Val-D-3-ClPhe/Thr-Nva-Ile-Arg-ProNHCH2CH3.
31110 July 21		(33)	N-Ac-Sar-Gly-Val-D-2-Thienylala-Thr-Nva-Ile-Arg-ProNHCH-CH2
# == ====	15	(34)	N-Ac-Sar-Gly-Val-D-3-CMPhe-Thr-Nva-Ile-Arg-ProNHCH2CH3.
74. H		(35)	N-Ac-Sar-Gly-Val-D-Ile-Thr-DNva-Ile-Arg-ProNHCH2CH2.
7U		(36)	N-Ac-Sar-Gly-Val-D-I/e-Thr-Gln-Ile-Arg-ProNHCH2CH3.
€Ō a		(37)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Cha-Ile-Arg-ProNHCH ₂ CH ₃ ,
4	20	(38)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Gly-Ile-Arg-ProNHCH ₂ CH ₃ ,
	20	(39)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Ala-Ile-Arg-ProNHCH ₂ CH ₃ ,
A. A. B. The start of the start		(40)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Val-Ile-Arg-ProNHCH ₂ CH ₃ ,
13		(41)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Abu-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(42)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Allylgly-Ile-Arg-ProNHCH ₂ CH ₃ ,
	25	(43)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Octylgly-Ile-Arg-ProNHCH ₂ CH ₃ ,
	23	(44)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Met-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(45)	N-Cyclohexylacetyl-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(46)	N-(2-Me-Nicotinyl)-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(47)	N-Succinyl-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	30	(48)	N-Nicofinyl-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	50	(49) (50)	N-Propionyl-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(50)	N-(MeO)acetyl-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(51)	N-(Shikimyl)-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(52)	N-(2-Furoyl)-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(

	(53)	N-Butyryl-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	(54)	N[2-THFcarbonyl]-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	(55)	N-[CH ₃ C(O)NH-(CH ₂) ₂ -O-(CH ₂) ₂ -O-CH ₂ -C(O)]-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
5	(56)	N[6-N-acetyl-(CH ₂) ₅ C(O)]-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
•	(57)	N-Hexanoyl-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	(58)	N-[4-N-Acetylaminobutyryl]-Sar-Gly-Val-D-lle-Thr-Nva-Ile-Arg- ProNHCH ₂ CH ₃ ,
10	(59)	H-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-PrøNHCH2CH3,
	(60)	N-Ac-Sar-Gly-Asn-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	(61)	N-[CH ₃ C(O)NH-(CH ₂) ₂ -O-(CH ₂) ₂ -O-(CH ₂ -C(O)]-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	(62)	N-Ac-Pro-Gly-Val-D-Ile-Thr-Nva-lle-Arg-ProNHCH2CH3,
15	(63)	N-Ac-Gly-Gly-Val-D-Ile-Thr-Nya-Ile-Arg-ProNHCH2CH3,
	(64)	N-Ac-Ala-Gly-Val-D-Ile-Thr-Xva-Ile-Arg-ProNHCH2CH3,
	(65)	N-Ac-NEtGly-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	(66)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Leu-Ile-Arg-ProNHCH2CH3,
	(67)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Ser-Ile-Arg-ProNHCH2CH3, ◀
20	(68)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH ₂ ,
	(69)	N-Ac-Sar-Gly-Val-D-Me-Thr-Nva-Ile-Arg-D-ProNHCH2CH3,
	(70)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-AbuNHCH ₂ CH ₃ ,
	(71)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Phe-NHCH ₂ CH ₃ ,
	(72)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Tic-NHCH ₂ CH ₃ ,
25	(73)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Hyp-NHCH ₂ CH ₃ ,
	(74)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Aib-NHCH2CH3,
	(75)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-D-Ala-NHCH ₂ CH ₃ ,
	(76)	N-Ac-Sar-Gy-Val-D-Ile-Thr-Nva-Ile-Arg-Pip-NHCH ₂ CH ₃ ,
	(77)	N-Ac-Sar-Gly-Val-D-Tyr(Et)-Thr-Nva-Ile-Arg-ProNHCH2CH3,
30	(78)	N-Ac-Sar-Gly-Val-D-Cys(tBu)-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	(79)	N-Ac-Sar-Gly-Val-D-Cys-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	(80)	N-Ac-sar-Gly-Val-D-Tyr(Bzl)-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	(81)	N-Ac/Sar-Gly-Val-D-Ser(Bzl)-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	(82)	N-Ac-Sar-Gly-Val-D-1Nal-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,

			/
		(83)	N-Ac-Sar-Gly-Val-D-tButylgly-Thr-Nva-Ile-Arg-ProNHCM2CH3,
		(84)	N-Ac-Sar-Gly-Val-D-Orn-Thr-Nva-Ile-Arg-ProNHCH2CH3,
		(85)	N-Ac-Sar-Gly-Val-D-Thr(Bzl)-Thr-Nva-Ile-Arg-ProNACH2CH3,
		(86)	N-Ac-Sar-Gly-Val-D-2Nal-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	5	(87)	N-Ac-Sar-Gly-Val-D-Phe(4-Me)-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(88)	N-Ac-Sar-Gly-Val-D-Phe(3,4-diMeO)-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(89)	N-Ac-Sar-Gly-Val-D-Phe(3,4,5-triF)-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(90)	N-Ac-Sar-Gly-Val-D-Phe(4-NO ₂)-Thr-Nva/lle-Arg-ProNHCH ₂ CH ₃ ,
		(91)	N-Ac-Sar-Gly-Val-D-Pen-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	10	(92)	N-Ac-Sar-Gly-Val-D-Pen(Acm)-Thr-Nya-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(93)	N-Ac-Sar-Gly-Val-D-Abu-Thr-Nva-Ile-Arg-ProNHCH2CH3,
		(94)	N-Ac-Sar-Gly-Val-D-Phe(4-NH ₂)-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
22 703		(95)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Ala-Arg-ProNHCH2CH3,
# # # # # # # # # # # # # # # # # # #		(96)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Met-Arg-ProNHCH2CH3,
=======================================	15	(97)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Phe-Arg-ProNHCH2CH3,
÷		(98)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Tyr-Arg-ProNHCH ₂ CH ₃ ,
		(99)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Nva-Arg-ProNHCH2CH3,
ar ar ar may way aya aya aya ay mak a		(100)	N-Ac-Sar-Gly-Val-D-Ley-Thr-Nva-Asp-Arg-ProNHCH2CH3,
		(101)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Gly-Arg-ProNHCH2CH3,
	20	(102)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Lys(Ac)-Arg-ProNHCH ₂ CH ₃ ,
		(103)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Leu-Arg-ProNHCH ₂ CH ₃ ,
		(104)	N-Ac-Sar-Gly-Val/D-Leu-Thr-Nva-2Nal-Arg-ProNHCH2CH3,
1.2		(105)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-1Nal-Arg-ProNHCH ₂ CH ₃ ,
		(106)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Allylgly-Arg-ProNHCH ₂ CH ₃ ,
	25	(107)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Cit-Arg-ProNHCH ₂ CH ₃ ,
		(108)	N-Ac-Sar-Gly-Val-D-Leu-Ala-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(109)	N-Ac-Sar-Gly-Val-D-Leu-Pro-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(110)	N-Ac-Sar-Gly-Val-D-Leu-Trp-Nva-Ile-Arg-ProNHCH2CH3,
		(111)	N-Ac-Sar-Gly-Val-D-Leu-Tyr-Nva-Ile-Arg-ProNHCH2CH3,
	30	(112)	N-Ac-Sar/Gly-Val-D-Leu-Nva-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(113)	N-Ac-Saf-Gly-Val-D-Leu-Gly-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(114)	N-Ac-Sar-Gly-Val-D-Leu-Lys(Ac)-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(115)	N-Ac-Sar-Gly-Val-D-Leu-2Nal-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,

		(116)	N-Ac-Sar-Gly-Val-D-Leu-1Nal-Nva-Ile-Arg-ProNHCH ₂ 9/H ₃ ,
		(117)	N-Ac-Sar-Gly-Val-D-Leu-Octylgly-Nva-Ile-Arg-ProNHCH2CH3,
		(118)	N-Ac-Sar-Gly-Val-D-Leu-Gln-Nva-Ile-Arg-ProNHCH2CH3,
		(119)	N-Ac-Sar-Gly-Val-D-Leu-Met-Nva-Ile-Arg-ProNHCH2CH3,
	5	(120)	N-Ac-Sar-Gly-Val-D-Leu-Ser-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(121)	N-Ac-Sar-Gly-Val-D-Leu-Allylgly-Nva-Ile-Arg/ProNHCH2CH3,
		(122)	N-Ac-Sar-Gly-Val-D-Leu-Ile-Nva-Ile-Arg-ProNHCH2CH3,
		(123)	N-Ac-Sar-Gly-Val-D-Leu-D-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(124)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Ile-Ile-Arg-ProNHCH ₂ CH ₃ ,
	10	(125)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nle-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(126)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Cit-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(127)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Met(O ₂)-Ile-Arg-ProNHCH ₂ CH ₃ ,
Par codes		(128)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-ProNHCH ₂ CH ₃ ,
H H L.A A		(129)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Tyr-/le-Arg-ProNHCH ₂ CH ₃ ,
# # # # # # # # # # # # # # # # # # #	15	(130)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Gly-Ile-Arg-ProNHCH2CH3,
		(131)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Lys(Ac)-Ile-Arg-ProNHCH ₂ CH ₃ ,
THE STATE STATE OF THE STATE OF		(132)	N-Ac-Sar-Gly-Val-D-Ile-ThryPropargylgly-Ile-Arg-ProNHCH ₂ CH ₃ ,
# H		(133)	N-Ac-Sar-Gly-Val-D-allolle-Thr-Gln-Ile-Arg-ProNHCH ₂ CH ₃ ,
# # #		(134)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Gln-Ile-Arg-ProNHCH2CH3,
ulta ndla Hana dhana ati'	20	(135)	N-Ac-Bala-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
₹IJ ₹IJ		(136)	N-Phenylacetyl-Sar-Gly-Val-D-lle-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
***		(137)	N-Ac-Sar-Gly-Val-D/lle-Thr-Nva-Ile-Arg-Pro-AzaglyNH ₂ ,
* # #		(138)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Sar-NHCH ₂ CH ₃ ,
		(139)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-SerNH ₂ ,
	25	(140)	N-Succinyl-Sar-Gly-Val-D-Leu-Thr-Nva-lle-Arg-ProNHCH2CH3,
		(141)	N-Ac-Sar-Ala-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,
		(142)	N-Ac-Sar-Leu-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,
		(143)	N-Ac-Sar-Phe-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,
		(144)	N-Ac-Sar-Glu-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	30	(145)	N-Ac-Sar-Pro-Val-D-Leu-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(146)	N-Ac-Sar-Asn-Val-D-Leu-Thr-Nva-Ile-Arg-ProNHCH2CH3,
		(147)	N-Ac-Saf-Asp-Val-D-Leu-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(148)	N-Ac-Asn-Gly-Val-D-Leu-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		. ,	

THE HEAT HEAT HEAT THE THE STATE WHAT HEAT HEAT HEAT HEAT HEAT HEAT HEAT H
The Real Res with the print work with the Real Real Real Real Real Real Real Rea
THE REST TO THE THE THE THE TENNE TH
THE REST TO THE THE THE THE TENNE TH
THE REST TO THE THE THE THE TENNE TH
The Harm He He
The Harm He He
The Harm He He
THE REEL OF THE
THE REAL OFF
11 11 11 11 11 11 11 11 11 11 11 11 11
11 11 11 11 11 11 11 11 11 11 11 11 11
. H H
, =
3 ===

		(149)	N-Ac-Gln-Gly-Val-D-Leu-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(150)	N-Ac-Ser-Gly-Val-D-Leu-Thr-Nva-Ile-Arg-ProNHQH ₂ CH ₃ ,
		(151)	N-Ac-Cit-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(152)	N-Ac-Glu-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	5	(153)	N-Ac-Gaba-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	-	(154)	N-Ac-Bala-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(155)	N-Ac-Gln-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(156)	N-Ac-Sar-Gly-Gly-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(157)	N-Ac-Sar-Gly-Glu-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	10	(158)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
		(159)	N-Succinyl-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(160)	N-Succinyl-Sar-Gly-Val-D-Leu-Thr-Gln-Ile-Arg-ProNHCH ₂ CH ₃ ,
==		(161)	N-Succinyl-Sar-Gly-Val-D-Leu-Thr-Gln-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
		(162)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Asp-Ile-Arg-ProNHCH ₂ CH ₃ ,
= = =	15	(163)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Asp-Ile-Arg-ProNHCH ₂ CH ₃ ,
-		(164)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Asn-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(165)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Met(O)-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(166)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Asn-Ile-Arg-ProNHCH2CH3,
:		(167)	N-Ac-Sar-Gly-Val-D-Thr-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	20	(168)	N-Ac-Sar-Gly-Val-D-Ser-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(169)	N-Ac-Sar-Gly-Val-D-Hser-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(170)	N-Ac-Sar-Gly-Val-D/Gln-Thr-Nva-Ile-Arg-ProNHCH2CH3,
		(171)	N-Ac-Sar-Gly-Val-D-Asn-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(172)	N-Ac-Sar-Gly-Val-D-Cit-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	25	(173)	N-Ac-Sar-Gly-Val-D-Hcit-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(174)	N-Ac-Sar-Gly-Val-D-Hle-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(175)	N-Ac-Sar-Gly-Val-D-Neopentylgly-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(176)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Phe(4-CONH ₂)-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(177)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-His-ProNHCH2CH3,
	30	(178)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Lys(Isp)-ProNHCH ₂ CH ₃ ,
		(179)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Lys(Nic)-ProNHCH2CH3,
		(180)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Orn(Nic)-ProNHCH ₂ CH ₃ ,
		(181)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Orn(Isp)-ProNHCH ₂ CH ₃ ,

(182)

(183)

(184)

(185)

(186)

(209) (210)

(211)

5

N-Ac-Sar-Gly-Val-D-allolle-Thr-Gln-Ile-Arg-ProNHCH₂(CH₃)₂,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-SarNH₂,


N-Ac-Sar-Gly-Val-D-allolle-Thr-Nva-Ile-Arg-Pro-SarNH₂,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Phe(4-NIsp)-ProNHCH₂CH₃, N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Cha(4-NIsp)-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Harg-ProNHCH2CH3,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Cit-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Norarg-ProNHCH₂CH₃,



		(272)	N-Ac-Sar-Gly-Val-D-allolle-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₂ OCH ₃ ,
		(273)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH2CH2OCH3,
		(274)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Ser-Ile-Arg-ProNHCH2CH2OCH3,
fft		(275)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Leu-Ile-Arg-ProNHCH2CH2OCH3,
	5	(276)	N-Succinyl-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH2OCH3,
		(277)	N-Succinyl-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH2CH2OCH3,
		(278)	N-Succinyl-Sar-Gly-Val-D-allolle-Thr-Gly-Ile-Arg-ProNHCH ₂ CH ₂ OCH ₃ ,
		(279)	N-Ac-Sar-Gly-Val-D-Ile-Ser-Nva-Ile-Arg-ProNHCH2CH2OCH3,
		(280)	N-Ac-Sar-Gly-Val-D-Leu-Ser-Nva-Ile-Arg-ProNHCH2CH2OCH3,
	10	(281)	N-Ac-Sar-Gly-Val-D-allolle-Thr-Allygly-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(282)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Allygly-Ile-Arg-ProNHCH2(CH3)2,
		(283)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Allygly-Ile-Arg-Pro-D-AlaNH ₂ ,
		(284)	N-Ac-Sar-Gly-Val-D-allolle-Thr-Allygly-Ile-Arg-Pro-D-AlaNH ₂ ,
H H H H L H L H		(285)	N-Succinyl-Sar-Gly-Val-D-Ile-Thr-Allygly-Ile-Arg-Pro-D-AlaNH ₂ ,
	15	(286)	N-Ac-Sar-Gly-Val-D-Ile-Ser-Allygly-Ile-Arg-Pro-ProNHCH ₂ CH ₃ ,
년 []		(287)	N-Ac-Sar-Gly-Val-D-Leu-Ser-Allygly-Ile-Arg-Pro-ProNHCH2CH3,
		(288)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-SarNH ₂ ,
Ī		(289)	N-Ac-Sar-Gly-Val-D-Me-Thr-Nva-Ile-Arg-ProNHOH,
		(290)	N-Ac-Sar-Gly-Val-D-Ile-Ser-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
# 	20	(291)	N-Ac-Sar-Gly-Val-D-allolle-Ser-Nva-Ile-Arg-ProNHCH2CH3,
H 15		(292)	N-Ac-Sar-Gly-Val-D-Leu-Hser-Nva-Ile-Arg-ProNHCH2CH3,
1		(293)	N-Ac-Sar-Gly-Gln-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(294)	N-Ac-Sar-Gly-Nva-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(295)	N-Ac-Sar-Gly-Ile-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	25	(296)	N-Ac-Sar-Gly-Phe-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(297)	N-Ac-Sar-Gly-Leu-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(298)	N-Ac-Saf-Gly-Ser-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(299)	N-Ac-Thr-Gly-Val-D-Leu-Thr-Nva-Ile-Arg-ProNHCH2CH3,
		(300)	N-Ac-sar-Gly-Val-D-allolle-Thr-Ala-Ile-Arg-ProNHCH2CH3,
	30	(301)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Ala-Ile-Arg-ProNHCH2(CH3)2,
		(302)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Ala-Ile-Arg-Pro-D-AlaNH ₂ ,
		(303)	N-Ac-Sar-Gly-Val-D-allolle-Thr-Ala-Ile-Arg-Pro-D-AlaNH ₂ ,
		(304)	N/Succinyl-Sar-Gly-Val-D-Ile-Thr-Ala-Ile-Arg-Pro-D-AlaNH ₂ ,

N-Ac-Sar-Gly-Val-D-Ile-Ser-Ala-Ile-Arg-ProNHCH₂CH₂

(305)


(338)

N-Ac-Sar-Gly-Val-D-allolle-Ser-Nva-Ile-Arg-ProNHCM₂(CH₃)₂,

- 220 -

		(371)	N-Ac-Sar-Gly-Val-D-Thr-Ser-Gln-Ile-Arg-ProNHCH ₂ CH ₂ ,
		(372)	N-(6-Ac-Aca)-Sar-Gly-Val-D-Leu-Ser-Gln-Ile-Arg-ProMHCH2(CH3)2,
		(373)	N-(6-Ac-Aca)-Sar-Gly-Val-D-Leu-Ser-Nva-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
		(374)	N-(4-Ac-Gaba)-Sar-Gly-Val-D-Leu-Ser-Gln-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
	5	(375)	N-(4-Ac-Gaba)-Sar-Gly-Val-D-Leu-Ser-Nva-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
		(376)	N-(2-Furoyl)-Sar-Gly-Val-D-Leu-Ser-Gln-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
		(377)	N-(2-Furoyl)-Sar-Gly-Val-D-Leu-Ser-Nva-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
		(378)	N-(Shikimyl)-Sar-Gly-Val-D-Leu-Ser-Gln-le-Arg-ProNHCH2(CH3)2,
		(379)	N-(Shikimyl)-Sar-Gly-Val-D-Leu-Ser-Nya-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
	10	(380)	N-(Shikimyl)-Sar-Gly-Val-D-Leu-Ser-Gln-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
		(381)	N-(Shikimyl)-Sar-Gly-Val-D-Leu-Sep-Nva-Ile-Arg-ProNHCH2(CH3)2,
		(382)	N-(2-Me-nicotinyl)-Sar-Gly-Val-D-Leu-Ser-Gln-Ile-Arg- ProNHCH ₂ (CH ₃) ₂ ,
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	15	(383)	N-(2-Me-nicotinyl)-Sar-Gly-Val-D-Leu-Ser-Nva-Ile-Arg- ProNHCH ₂ (CH ₃) ₂ ,
= == == ===		(384)	N-Ac-Sar-Gly-Val-D-Leu-Ser-Nva-Ile-Arg-ProNHethyl-1-(R)-cyclohexyl,
÷ ₽11		(385)	N-Ac-Sar-Gly-Val-D-Leu-Ser-Gln-Ile-Arg-ProNHethyl-1-(R)-cyclohexyl,
Fig. 1120 Mill		(386)	N-Ac-Sar-Gly-Val-DIle-Thr-Ser-Ile-Arg-ProNHethyl-1-(R)-cyclohexyl,
E.		(387)	N-Ac-Sar-Gly-Val-D-Leu/Thr-Nva-Ile-Arg-ProNHethyl-1-(R)-cyclohexyl,
<u> </u>	20	(388)	N-Ac-Sar-Gly-Val-D-Leu-Ser-Ser-Ile-Arg-ProNHethyl-1-(R)-cyclohexyl,
148 1114 1114 Hans		(389)	N-Ac-Sar-Gly-Val-DIIg-Thr-Nva-Ile-Arg-ProNHethyl-1-(S)-cyclohexyl,
C. S. C. S. C. S.	·	(390)	N-Ac-Sar-Gly-Val-D-Pen-Ser-Nva-Ile-Arg-ProNHCH2CH3,
1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1		(391)	N-Ac-Sar-Gly-Val-19-Pen-Gly-Nva-Ile-Arg-ProNHCH2CH3,
		(392)	N-Ac-Sar-Gly-Val-D-Pen-Thr-Gln-Ile-Arg-ProNHCH2CH3,
	25	(393)	N-Ac-Sar-Gly-Val-D-Pen-Ser-Nva-Ile-Arg-ProNHCH2(CH3)2,
		(394)	N-Succinyl-Sar-Gly-Val-D-Pen-Ser-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(395)	N-Ac-Sar-Gly-Val-D-Pen-Ser-Nva-Ile-Arg-Pro-D-AlaNH ₂ ,
		(396)	N-Ac-Sar-Gly-Val-D-Pen-Ser-Gln-Ile-Arg-ProNHCH2CH3,
		(397)	N-Ac-Sar-Gly-Val-D-Pen-Gly-Gln-Ile-Arg-ProNHCH2CH3,
	30	(398)	N-Ac-Sar-Gly-Val-D-Pen-Ser-Ser-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(399)	N-Ac-Sar/Gly-Val-D-Pen-Thr-Ser-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(400)	N-Ac-Sar-Gly-Val-D-Pen-Thr-Leu-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(401)	N-Ac-Şar-Gly-Val-D-Pen-Ser-Leu-Ile-Arg-ProNHCH ₂ CH ₃ ,
		•	

			/
		(402)	N-Succinyl-Sar-Gly-Val-D-Pen-Ser-Ser-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(403)	N-Succinyl-Sar-Gly-Val-D-Pen-Ser-Leu-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(404)	N-Succinyl-Sar-Gly-Val-D-Pen-Thr-Gln-Ile-Arg-ProNHCH2(CH3)2,
		(405)	N-Ac-Sar-Gly-Val-D-Cys-Thr-Nva-Ile-Arg- ProNICH2CH3,
	5	(406)	N-Ac-Sar-Gly-Val-D-Cys-Ser-Nva-Ile-Arg-ProMHCH2CH3,
		(407)	N-Ac-Sar-Gly-Val-D-Cys-Gly-Nva-Ile-Arg-ProNHCH2CH3,
		(408)	N-Ac-Sar-Gly-Val- D-Cys-Thr-Gln-Ile-Arg/ProNHCH2CH3,
		(409)	N-Ac-Sar-Gly-Val-D-Cys-Ser-Nva-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
		(410)	N-Succinyl-Sar-Gly-Val-D-Cys-Ser-Nya-Ile-Arg-ProNHCH2CH3,
	10	(411)	N-Ac-Sar-Gly-Val-D-Cys-Ser-Nva-Ile-Arg-Pro-D-AlaNH ₂ ,
		(412)	N-Ac-Sar-Gly-Val-D-Cys-Ser-Gln-Tle-Arg-ProNHCH2CH3,
		(413)	N-Ac-Sar-Gly-Val-D-Cys-Gly-Gln-Ile-Arg-ProNHCH2CH3,
7		(414)	N-Ac-Sar-Gly-Val-D-Cys-Ser-Ser-Ile-Arg-ProNHCH2CH3,
		(415)	N-Ac-Sar-Gly-Val-D-Cys-Thr-Ser-Ile-Arg-ProNHCH2CH3,
:	15	(416)	N-Ac-Sar-Gly-Val-D-Cys-Thr-Leu-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(417)	N-Ac-Sar-Gly-Val-D-Cys-Ser-Leu-Ile-Arg-ProNHCH2CH3,
		(418)	N-Succinyl-Sar-Gly-Val-p-Cys-Ser-Ser-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(419)	N-Succinyl-Sar-Gly-Val-D-Cys-Ser-Leu-Ile-Arg-ProNHCH ₂ CH ₃ ,
:		(420)	N-Ac-Sar-Gly-Pen-DILE-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	20	(421)	N-Ac-Sar-Gly-Cys-Dile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(422)	N-Ac-Sar-Gly-Pen-D-allolle-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(423)	N-Ac-Sar-Gly-Pen-D-Leu-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(424)	N-Ac-Sar-Gly-Pen-D-Ile-Thr-Gln-Ile-Arg-ProNHCH2CH3,
		(425)	N-Ac-Sar-Gly-Pen-D-Ile-Ser-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	25	(426)	N-Ac-Sar-Gly-Pen-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2(CH3)2,
		(427)	N-Ac-Sar-Gly-Pen-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH ₂ ,
		(428)	N-Succinyl-Gly-Pen-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(429)	N-Succinyl-Sar-Gly-Pen-D-Ile-Thr-Gln-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(430)	N-Succinyl-Sar-Gly-Pen-D-Ile-Thr-Gln-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
	30	(431)	N-Ac-Sar-Gly-Val-D-Leu-Pen-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(432)	N-Ac-\$ar-Gly-Val-D-Ile-Pen-Nva-Ile-Arg-ProNHCH2CH3,
		(433)	N-Ac-Sar-Gly-Val-D-allolle-Pen-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,



		(464)	N-Ac-Sar-Ala-Val-D-Leu-Ser-Nva-Ile-Arg-ProNHCH2CH3,
		(465)	N-Ac-Sar-Ala-Val-D-Leu-Ser-Gln-Ile-Arg-ProNHCH2CH3,
		(466)	N-Succinyl-Sar-Ala-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,
		(467)	N-Succinyl-Sar-Ala-Val-D-Ile-Thr-Gln-Nva-Ile-Arg-ProNHCH2CH3,
	5	(468)	N-Succinyl-Sar-Ala-Val-D-Ile-Thr-Gln-Nva-Le-Arg-ProNHCH2(CH3)2,
		(469)	N-Succinyl-Sar-Ala-Val-D-Ile-Thr-Gln-Nya-Ile-Arg-Pro-D-AlaNH ₂ ,
		(470)	N-(3-Ac-Bala)-Sar-Gly-Val-D-allolle-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(471)	N-(3-Ac-Bala)-Sar-Gly-Val-D-Ile-Thr/Gln-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(472)	N-(3-Ac-Bala)-Sar-Gly-Val-D-allolle-Thr-Gln-Ile-Arg-ProNHCH2CH3,
	10	(473)	N-(3-Ac-Bala)-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-Pro-DAlaNH2,
		(474)	N-(3-Ac-Bala)-Sar-Gly-Val-D-allolle-Thr-Gln-Ile-Arg-Pro-DAlaNH2,
		(475)	N-(3-Ac-Bala)-Sar-Gly-Val-D-allolle-Thr-Gln-Ile-Arg-ProNHCH ₂ (CH ₃) ₂ ,
		(476)	N-(3-Ac-Bala)-Sar-Gly-Val/D-Leu-Ser-Nva-Ile-Arg-ProNHCH2CH3,
=======================================		(477)	N-(3-Ac-Bala)-Sar-Gly-Val-D-Leu-Thr-Nva-Ile-Arg-ProNHCH2CH3,
THE RESERVE THE REPORT OF THE RESERVE THE	15	(478)	N-(3-Ac-Bala)-Sar-Gly-Val-D-Pen-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
11		(479)	N-(3-Ac-Bala)-Sar-Gly-Val-D-Ile-Ser-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
fu fn		(480)	N-(3-Ac-Bala)-Sar-Ala-Val-D-alloIle-Ser-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
£		(481)	N-(3-Ac-Bala)-Sar-Ala-Val-D-Ile-Ser-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
; - \$ =		(482)	N-(3-Ac-Bala)-Sar-Ala-Val-D-Leu-Ser-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
THE CHEST CONTRACTOR AND ACTION ACTION AND ACTION AND ACTION ACTION AND ACTION ACTION AND ACTION ACTION AND ACTION ACT	20	(483)	N-(3-Ac-Bala)-sar-Ala-Val-D-Leu-Ser-Gln-Ile-Arg-ProNHCH ₂ CH ₃ ,
1		(484)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-OH,
≒±i		(485)	N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-Pro-OH,
		(486)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Ile-Arg-Pro-OH,
		(487)	N-Ac-Sar-Gly-Val-D-Pen-Thr-Nva-Ile-Arg-Pro-OH,
	25	(488)	N-Ac-Sar-Gly-Val-D-Phe(3,4,5-triF)-Thr-Nva-Ile-Arg-Pro-OH,
		(489)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-Pro-OH,
		(490)	N-Ac-Sar-Gly-Val-D-Leu-Ser-Nva-Ile-Arg-Pro-OH,
		(491)	N-Ac-Sar-Ala-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-OH,
		(492)	N-Ac-Sar-Gly-Val-D-Ile-Ser-Gln-Ile-Arg-Pro-OH,
	30	(493)	N-Succinyl-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-OH,
		(494)	N-Succinyl-Sar-Gly-Val-D-Leu-Thr-Gln-Ile-Arg-Pro-OH,
		(495)	N-Ac-Sar-Gly-Asp-D-Leu-Thr-Nva-Ile-Arg-ProNHCH2CH3,

N-Ac-Sar-Gly-Ala-D-Leu-Thr-Nva-Ile-Arg-ProNHCH2CH3,

N-Ac-Sar-Gly-Cha-D-Leu-Thr-Nva-Ile-Arg-ProNHCH2CH3,

N-Ac-Sar-Gly-Met-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,

(496)

(497)

(498)

(12)

(13)

N-Ac-Sar-Gly-Val-D-3-ClPhe-Thr-Nva-Ile-Arg-ProNHCH₂CH₃.

N-Ac-Sar-Gly-Val-D-2-Thienylala-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,

	5	(17)	N[6-N-acetyl-(CH ₂) ₅ C(O)]-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(18)	N-Hexanoyl-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(19)	N-[4-N-Acetylaminobutyryl]-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	10	(20)	$N-[CH_3C(O)NH-(CH_2)_2-O-(CH_2)_2-O-CH_2-C(O)]-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH_2CH_3,$
		(21)	N-Ac-Pro-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(22)	N-Ac-NEtGly-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(23)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Leu-Ile-Arg-ProNHCH ₂ CH ₃ ,
ĒĴ		(24)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Ser-Ile-Arg-ProNHCH ₂ CH ₃ ,
	15	(25)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH ₂ ,
===		(26)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Lys(Ac)-Arg-ProNHCH ₂ CH ₃ ,
٠		(27)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Leu-Arg-ProNHCH ₂ CH ₃ ,
Fr. 6		(28)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-1Nal-Arg-ProNHCH ₂ CH ₃ ,
an This		(29)	N-Ac-Sar-Gly-Val-D-Leu-Thr-Nva-Allylgly-Arg-ProNHCH ₂ CH ₃ ,
흩퍧	20	(30)	N-Ac-Sar-Gly-Val-D-Leu-Ala-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
4 14		(31)	N-Ac-Sar-Gly-Val-D-Leu-Trp-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
r <u>u</u>		(32)	N-Ac-Sar-Gly-Val-D-Leu-Tyr-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
Harry Harry		(33)	N-Ac-Sar-Gly-Val-D-Leu-Gly-Nva-Ile-Arg-ProNHCH2CH3,
7 00		(34)	N-Ac-Sar-Gly-Val-D-Leu-2Nal-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
	25	(35)	N-Ac-Sar-Gly-Val-D-Leu-1Nal-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(36)	N-Ac-Sar-Gly-Val-D-Leu-Octylgly-Nva-Ile-Arg-ProNHCH2CH3,
		(37)	N-Ac-Sar-Gly-Val-D-Leu-Ser-Nva-Ile-Arg-ProNHCH ₂ CH ₃ ,
		(38)	N-Ac-Sar-Gly-Val-D-Leu-Allylgly-Nva-Ile-Arg-ProNHCH2CH3,
		(39)	N-Ac-Sar-Gly-Val-D-Leu-D-Thr-Nva-Ile-Arg-ProNHCH2CH3,
	30	(40)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Tyr-Ile-Arg-ProNHCH2CH3,
		(41)	N-Ac-Sar-Gly-Val-D-Ile-Thr-Glu-Ile-Arg-ProNHCH2CH3,

(14)

(15)

(16)

(42)

(43)

(44)

N-Ac-Sar-Gly-Val-D-Ile-Thr-Propargylgly-Ile-Arg-ProNHCH2CH3,

N-Ac-Sar-Gly-Val-D-allolle-Thr-Gln-Ile-Arg-ProNHCH2CH3,


N-Ac-Bala-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3,

N-Ac-Sar-Gly-Val-D-3-CNPhe-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,

N[2-THF-C(O)]-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Cha-Ile-Arg-ProNHCH₂CH₃,

(64)



14. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

N-Ac-Sar-Gly-Val-D-Phe(4-NH₂)-Thr-Nva-Ile-Arg-ProNHCH₂CH₃.

- 15. A method of treating a patient in need of anti-angiogenesis therapy comprising administering to the patient in need a therapeutically effective amount of a compound in Claim 1.
- 16. A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention,

macular degeneration and diabetic retinopathy comprising a peptide as defined in Claim 1 in combination with a pharmaceutically acceptable carrier.

17. A method of isolating a receptor from an endothelial cell comprising binding a peptide as defined in Claim 1 to the receptor to form a peptide receptor complex; isolating the peptide receptor complex; and purifying the receptor.